Previous 10 | Next 10 |
home / stock / abbv / abbv articles
On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Eve...
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net...
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. AI giants&nb...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapad...
On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc’s (NYSE:ABB...
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 15.8%. C...
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and ...
Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulation...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...